Individual patient characteristics and responses
| Patient number | Age (years) | R-ISS | Induction regimen | Pre-ASCT response | Best post-ASCT response | Post-ASCT consolidation | Post-ASCT maintenance |
| Control | |||||||
| 1 | 64 | 2 | VRd | PR | PR | VRd×2 | None* |
| 2 | 50 | 2 | VRd | sCR | MRD-neg sCR | None | R |
| 3 | 60 | 2 | VRd | PR | PR | VRd×4 | VRd |
| 4 | 56 | 3 | Rd | VGPR | sCR | None | R |
| 5 | 71 | 2 | KRd | PR | MRD-neg sCR | None | R |
| IVTRD | |||||||
| 6 | 49 | 2 | VRd | PR | VGPR | None | R |
| 7 | 62 | 1 | Vd | MRD-neg sCR | sCR | VRd×2 | R |
| 8 | 65 | 1 | VRd | VGPR | MRD-neg sCR | VRd×4 | R |
| 9 | 65 | 1 | VRd | CR | sCR | None | R |
| EVTRD | |||||||
| 10 | 57 | N/A | VRd | PR | MRD-neg sCR | None | R |
| 11 | 46 | 1 | VRd | sCR | sCR | VRd×2 | R |
| 12 | 67 | 2 | VRd | PR | MRD-neg sCR | VRd×2 | R |
| 13 | 64 | 2 | VRd | VGPR | MRD-neg sCR | KRd×8 | R |
| 14 | 53 | 1 | VRd | PR | MRD-neg sCR | None | R |
*Patient declined maintenance therapy.
ASCT, autologous stem cell transplant; CR, complete response; EVTRD, ex vivo Treg depletion; IVTRD, in vivo Treg depletion;KRd, carfilzomib, lenalidomide, and dexamethasone; MRD-neg, minimal residual disease negative; PR, partial response; R, lenalidomide;Rd, lenalidomide+dexamethasone; R-ISS, Revised-International Staging System; sCR, stringent complete response;Vd, bortezomib+dexamethasone; VGPR, very good partial response; VRd, bortezomib, lenalidomide, and dexamethasone .